Details of the Drug Combination

General Information of Drug Combination (ID: DCLUYI5)

Drug Combination Name

Arfolitixorin TEM

Indication

Disease Entry	Status	REF
Minimally invasive lung adenocarcinoma	Investigative	[1]

Component Drugs

Arfolitixorin DMIXMYK

TEM DMLNFWU

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: NCI-H322M

Zero Interaction Potency (ZIP) Score: 5.1

Bliss Independence Score: 10.08

Loewe Additivity Score: 4.47

LHighest Single Agent (HSA) Score: 7.8

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adenocarcinoma	DCRJT9G	HCT116	Investigative	[1]
Adenocarcinoma	DC7FGX9	SW-620	Investigative	[1]
Large cell lung carcinoma	DCS7SA7	NCI-H460	Investigative	[1]
Prostate carcinoma	DCZSVYG	PC-3	Investigative	[1]
------------------------------------------------------------------------------------

References

1	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2	ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030055)